Evidence map›Paper›PMID 34947993›Full record

ArticleInternational journal of molecular sciences2021

Evaluation of the Central Effects of Systemic Lentiviral-Mediated Leptin Delivery in Streptozotocin-Induced Diabetic Rats.

Kimberly A Clark, Andrew C Shin, Madhu P Sirivelu, Ramya C MohanKumar, Sreenivasa R Maddineni, Ramesh Ramachandran, Puliyur S MohanKumar, Sheba M J MohanKumar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Kimberly A ClarkNeuroscience Graduate Program, Michigan State University, E. Lansing, MI 48824, USA.
Andrew C ShinNeurobiology of Nutrition Laboratory, Department of Nutritional Sciences, College of Human Sciences, Texas Tech University, Lubbock, TX 79409, USA.ORCID 0000-0002-4748-5135
Madhu P SiriveluPathobiology and Diagnostic Investigation, Michigan State University, E. Lansing, MI 48824, USA.
Ramya C MohanKumarNeuroendocrine Research Laboratory, University of Georgia, Athens, GA 30602, USA.
Sreenivasa R MaddineniDepartment of Poultry Science, College of Agricultural Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Ramesh RamachandranDepartment of Poultry Science, College of Agricultural Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Puliyur S MohanKumarNeuroscience Graduate Program, Michigan State University, E. Lansing, MI 48824, USA.
Sheba M J MohanKumarNeuroscience Graduate Program, Michigan State University, E. Lansing, MI 48824, USA.ORCID 0000-0002-3365-7864
University of Georgia · USMichigan State University · USPennsylvania State University · USTexas Tech University · US

Funding

National Science Foundation IBN 0236385NIH HHS NIH R01AG 027697
6 · The paper itself

Abstract

Type 1 diabetes (T1D) is characterized by hyperphagia, hyperglycemia and activation of the hypothalamic-pituitary-adrenal (HPA) axis. We have reported previously that daily leptin injections help to alleviate these symptoms. Therefore, we hypothesized that leptin gene therapy could help to normalize the neuroendocrine dysfunction seen in T1D. Adult male Sprague Dawley rats were injected i.v. with a lentiviral vector containing the leptin gene or green fluorescent protein. Ten days later, they were injected with the vehicle or streptozotocin (STZ). HPA function was assessed by measuring norepinephrine (NE) levels in the paraventricular nucleus (PVN) and serum corticosterone (CS). Treatment with the leptin lentiviral vector (Lepvv) increased leptin and insulin levels in non-diabetic rats, but not in diabetic animals. There was a significant reduction in blood glucose levels in diabetic rats due to Lepvv treatment. Both NE levels in the PVN and serum CS were reduced in diabetic rats treated with Lepvv. Results from this study provide evidence that leptin gene therapy in STZ-induced diabetic rats was able to partially normalize some of the neuroendocrine abnormalities, but studies with higher doses of the Lepvv are needed to develop this into a viable option for treating T1D.

Indexed as

AnimalsCorticosteroneDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Disease Models, AnimalGenetic TherapyGenetic VectorsInjections, IntravenousLentivirusLeptinMaleNorepinephrineParaventricular Hypothalamic NucleusRatsRats, Sprague-DawleyCorticosteroneLEP protein, humanLeptinNorepinephrinecorticosteronediabetesgene transferhypothalamusleptinnorepinephrinestress

Identifiers

PMID34947993
PMCPMC8703968
OpenAlexW4200204298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.